Legend Biotech Corporation (LEGN)
LEGNNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$24.50
+1.31 (+5.65%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $4.72bn
- P/E
- –
- EPS, last 4 quarters
- $-0.2500
- Dividend yield
- –
- Day range
- –
- 52-week range
- $16.24 to $37.50
- Average volume
- 2.08m
- Previous close
- $23.19
Analysts
11 coveringBuy6 buy, 5 hold, 0 sell
Targets a year out average $46.01, +87.8% from here
Earnings
next estimate $0.0100Next report Nov 10, 2026
Sep 2025
+15.4%
Dec 2025
+52.9%
Mar 2026
-650.0%
Jun 2026
-25.0%
estimate reported, and the surprise
Financials
| Quarter | Mar 2020 |
|---|---|
| Revenue | $11.55m |
| Gross profit | $11.55m |
| Operating income | -$43.95m |
| Net income | -$44.23m |
News
8 latest- Legend Biotech Announces 7 Presentations at the 68th American Society of Hematology Annual MeetingFintel · 5 days ago
- Legend Biotech Corporation Sponsored ADR (LEGN) Crossed Above the 50-Day Moving Average: What That Means for InvestorsZacks · Oct 27, 2026
- Legend Biotech Wins FDA Clearance For In Vivo CAR-T Therapy LB2501; Stock Up RTTNews · Oct 15, 2026
- Legend Biotech Appoints Ingrid Zhang As CEO RTTNews · Sep 15, 2026
- After Hours Most Active for Sep 11, 2026 : KHC, ACWX, PATH, TSLL, GRAB, F, LEGN, AAPL, XPEV, KVUE, T, BMNRNASDAQ.com · Sep 11, 2026
- Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.The Motley Fool · Aug 31, 2026
- Legend Turns Profitable In Q2 As CARVYKTI Sales Jump By 50% RTTNews · Aug 12, 2026
- Legend Biotech (LEGN) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 11, 2026
The company
With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI's patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- legendbiotech.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.